for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abbott Laboratories

ABT.N

Latest Trade

85.97USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

65.44

 - 

88.76

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
85.97
Open
--
Volume
--
3M AVG Volume
96.61
Today's High
--
Today's Low
--
52 Week High
88.76
52 Week Low
65.44
Shares Out (MIL)
1,768.46
Market Cap (MIL)
150,159.60
Forward P/E
26.19
Dividend (Yield %)
1.51

Next Event

Q4 2019 Abbott Laboratories Earnings Release

Latest Developments

More

Abbott Says Robert Ford To Succeed Miles White As Chief Executive Officer

FDA Says Abbott Recalled Centrimag Circulatory Support System Motor

Abbott Reports Third-Quarter 2019 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry

Medical Equipment & Supplies

Contact Info

100 Abbott Park Rd

+1.224.6676100

http://www.abbott.com

Executive Leadership

Miles D. White

Chairman of the Board, Chief Executive Officer

Robert B. Ford

President, Chief Operating Officer

Brian B. Yoor

Chief Financial Officer, Executive Vice President - Finance

Hubert L. Allen

Executive Vice President, General Counsel, Secretary

Jaime Contreras

Senior Vice President - Core Laboratory Diagnostics, Commercial Operations

Key Stats

1.74 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

20.9K

2017

27.4K

2018

30.6K

2019(E)

31.9K
EPS (USD)

2016

2.200

2017

2.500

2018

2.880

2019(E)

3.243
Price To Earnings (TTM)
45.90
Price To Sales (TTM)
4.79
Price To Book (MRQ)
4.72
Price To Cash Flow (TTM)
23.79
Total Debt To Equity (MRQ)
60.02
LT Debt To Equity (MRQ)
55.44
Return on Investment (TTM)
5.65
Return on Equity (TTM)
4.70

Latest News

Latest News

Abbott CEO Miles White to step down next year

Abbott Laboratories <ABT.N> longtime Chief Executive Officer Miles White will step down in favour of his chief of operations in March, handing over the reins after successfully reshaping the healthcare conglomerate in a series of transformative deals.

Abbott CEO Miles White to step down next year

Abbott Laboratories said on Wednesday Chief Executive Officer Miles White would step down next year and be replaced by Chief Operating Officer Robert Ford.

FDA classifies Abbott's blood pumping system recall as most serious

The U.S. Food and Drug Administration on Monday classified the recall of Abbott Laboratories' CentriMag blood pumping system following the death of a patient, as Class 1 or the most serious type of recall.

Abbott revenue misses as heart devices eclipse diabetes gains

Abbott Laboratories <ABT.N> fell just short of Wall Street estimates for quarterly revenue on Wednesday, as weakness in the medical device maker's cardiovascular business overshadowed strong performance in its fast-growing diabetes care unit.

Abbott hits record high as diabetes device fuels profit beat

Abbott Laboratories <ABT.N> beat analysts' estimates for quarterly profit and lifted its full-year earnings forecast on Wednesday, boosted by a near 64% jump in sales of its blood sugar monitoring device.

Abbott to hike production of lower-cost glucose monitors as diabetes soars

Abbott Laboratories <ABT.N> plans to ramp up manufacturing capacity for its lower-cost continuous glucose monitor, the FreeStyle Libre, by three to five times in the next few years, aiming to reach millions more patients worldwide, the company told Reuters.

Abbott device helps in cutting blood sugar in type 2 diabetics: study

Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday.

Abbott Labs quarterly beat overshadowed by unchanged forecast

Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.

Abbott Lab's first-quarter sales beat expectations

Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.

Abbott misses revenue estimates, sees lackluster first-quarter profit

Abbott Laboratories <ABT.N> missed analysts' estimates for fourth-quarter revenue on Wednesday due to lower sales of its generic drugs in emerging markets as well as a strong dollar, and also forecast current-quarter profit below expectations.

Abbott Labs says M&A not a high priority now

Healthcare company Abbott Laboratories <ABT.N> will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

Abbott Labs says M&A not a high priority now

Healthcare company Abbott Laboratories will not focus on mergers and acquisitions in the near future, Chief Executive Officer Miles White said on a conference call on Wednesday.

Abbott Lab's fourth-quarter revenue rises 2.3 pct

Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices.

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Abbott, AbbVie settle U.S. case over TriCor marketing for $25 mln

Abbott Laboratories and AbbVie Inc will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for them prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Abbott Labs quarterly profit falls on higher tax expense

Abbott Laboratories <ABT.N> reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

Abbott Labs quarterly profit falls 6.6 pct on tax expense

Diversified healthcare company Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.

Abbott Labs raises 2018 earnings forecast, shares hit record high

Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.

Abbott Labs tops profit estimates, raises full-year earnings forecast

Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.

Allergan appoints former Abbott executive to its board

Allergan Plc <AGN.N> said on Thursday former Abbott Laboratories <ABT.N> executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up